Abstract
OBJECTIVE. FDG PET/CT is emerging as an important modality in the evaluation of pleural tumors. PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma. This modality has distinct advantages in characterizing other primary pleural tumors and pleural metastases.
CONCLUSION. FDG PET/CT is a useful imaging modality in the management of patients with primary pleural tumors and pleural metastases.